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We report the first two cases of Trichosporon mycotoxinivorans infections in Latin America. We also conduct-
ed a literature review and a microbiological investigation, including that of clinical and environmental isolates. A 
30-year-old man with chronic renal failure had disseminated infection after dialysis and a 15-year-old boy with cys-
tic fibrosis (CF) had pulmonary exacerbations with positive respiratory samples. A review of the relevant literature 
revealed that deep-seated infections were related to immunosuppression or invasive devices, while most of the CF 
patients showed a decline in lung function after positive cultures. Phylogenetic analyses revealed three distinct circu-
lating genotypes. MALDI-TOF mass spectrometry analysis showed similar spectral profiles and correctly identified 
all strains/isolates. Biofilm production was documented in a bloodstream isolate and biofilm-producing cells showed 
high minimum inhibitory concentrations against antifungals.
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The basidiomycetous yeast, Trichosporon mycotox-
inivorans (T. mycotoxinivorans) was first described in 
2004 (Molnar et al. 2004). T. mycotoxinivorans has been 
proposed as a microbial feed additive against mycotoxins 
produced by moulds, protecting livestock from intoxica-
tion after consumption of contaminated crop (Politis et 
al. 2005). Moreover, in Brazil, T. mycotoxinivorans was 
recovered from effluents of the dairy industry (Monteiro 
et al. 2010) and has been studied for the bioconversion of 
biodiesel refinery waste (Monteiro et al. 2012). Howev-
er, since 2009, this microorganism has been considered 
a new pathogen for patients with cystic fibrosis (CF) 
(Hickey et al. 2009). In 2015, Liu and collaborators con-
ducted an in-depth phylogenetic reclassification of the 
tremellomycetous yeasts, proposing a new genus name 
to T. mycotoxinivorans, and that is Apiotrichum myco-
toxinivorans (A. mycotoxinivorans) (Liu et al. 2015).
In order to provide additional data to the current 
knowledge regarding this emergent microorganism, we 
report clinical data regarding the first two cases of T. 
mycotoxinivorans (A. mycotoxinivorans) deep-seated 
infections documented in Latin America, along with a 
brief literature review. Clinical isolates were character-
ised by IGS rDNA sequencing, proteomic profile (MAL-
DI-TOF), and capability to produce biofilms.
In December 2010, a 30-year-old male patient with 
a history of chronic renal failure was admitted to a ter-
tiary hospital in Salvador, presenting with altered level of 
consciousness after a peritoneal dialysis session. On day 
3, the patient was diagnosed with sepsis, and blood and 
peritoneal fluid cultures were collected for microbiologi-
cal investigation. The peritoneal fluid became positive 
for Trichosporon sp. after two days of incubation (day 
5). Despite antifungal therapy [amphotericin B (AMB) 
deoxycholate, 40 mg/day] prescribed on day 5, the pa-
tient’s fever persisted, and he developed multiple pulmo-
nary infiltrates and respiratory failure. Blood cultures 
collected on day 12 also became positive for Trichosporon 
spp. (isolate L7537) and antifungal therapy was changed 
to voriconazole on day 14 (300 mg q 12 h on the first day, 
then 200 mg q 12 h). The attempts to remove the Tenck-
hoff and haemodialysis catheters were unsuccessful, and 
the patient’s condition deteriorated due to sepsis by Chry-
seobacterium meningosepticum, and he died on day 29.
The second case was a 15-year-old boy from a city 
near São Paulo (Guaratinguetá) with a diagnosis of CF 
(CFTR genotype F508del and G542X) and multiple pul-
monary exacerbations, receiving intermittent treatment 
with antibiotics. In September 2014, another pulmonary 
exacerbation was diagnosed with a significant decline in 
lung function (42 to 28% of predicted forced expiratory 
volume in the first second - FEV1). At that time (day 0), 
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the sputum culture became positive for Trichosporon spp. 
(isolate L998/16). Due to the persistent positive sputum 
cultures and since the FEV1 values remained below 40%, 
a long course therapy with fluconazole (150 mg/day for 21 
days) was started (day 210). Sputum cultures became neg-
ative (days 300, 390, 480) and the patient exhibited partial 
recovery of the lung function (FEV1 39%). However, spu-
tum cultures became positive for Trichosporon spp. once 
again (day 600) and antifungal treatment is being envis-
aged in case of a new episode of pulmonary exacerbation.
Both clinical isolates (L7537 and L998/16) were iden-
tified as T. mycotoxinivorans (A. mycotoxinivorans) after 
sequence analysis of the IGS1 region from the rDNA (see 
microbiological investigation below). In accordance with 
the standard definitions of opportunistic invasive fungal 
infections (de Pauw et al. 2008) adapted by Colombo et 
al. (2011) for investigating Trichosporon spp. infections, 
we considered case one and case two as proven and prob-
able deep-seated trichosporonosis, respectively.
As detailed in the supplementary material (Supple-
mentary data, Table), only four cases of T. mycotoxini-
vorans fungaemia have been reported thus far, one CF 
patient after lung transplantation, one patient with acute 
promyelocytic leukaemia and neutropaenia, and another 
two critically ill patients who were exposed to invasive 
medical procedures (Hirschi et al. 2012, Dabas et al. 2016). 
All these patients died despite administration of antifungal 
therapy, which consisted of initial liposomal amphotericin 
B (AMB) replaced by voriconazole (n = 1), voriconazole 
monotherapy (n = 1), caspofungin monotherapy (n = 1), 
and deoxycholate AMB monotherapy (n = 1).
The distinction of pulmonary colonisation or infection 
by T. mycotoxinivorans (A. mycotoxinivorans) in non-im-
munosuppressed CF patients is a matter of debate that 
has been recently raised by different investigators. Ac-
cording to Esther Jr et al. (2016), CF patients with respira-
tory samples positive for T. mycotoxinivorans may exhib-
it lung function decline over time when compared to CF 
patients with negative cultures. These findings suggest 
that this microorganism may not be simply a coloniser of 
the respiratory tract of CF patients. Indeed, among eight 
well-documented cases of non-immunosuppressed CF 
patients reported with positive respiratory samples for T. 
mycotoxinivorans (A. mycotoxinivorans) (Supplementary 
data, Table), six showed a decline in lung function after 
the first positive culture (Kröner et al. 2013, Shah et al. 
2014, Goldenberger et al. 2016, Muñiz et al. 2016). Con-
solidating our case with the information provided by the 
literature review summarised above, we suggest that T. 
mycotoxinivorans (A. mycotoxinivorans) may colonise 
and infect the respiratory tract of CF patients, causing 
progressive deterioration of their lung function.
Finally, we carried out a microbiological analysis of 
clinical (L7537, L998/16) and environmental (L1024/16)
isolates, and reference strains (CBS9756 and CBS10094) 
of T. mycotoxinivorans (A. mycotoxinivorans). The mi-
crobiological analysis included investigation of genetic 
and proteomic diversity, as well as of biofilm production 
Biofilm quantification of Trichosporon mycotoxinivorans (Apiotrichum mycotoxinivorans) isolates and MIC values of planktonic (Pkt) and 
biofilm (Bfm) forming cells at 48 h readings. Reference strains are presented in white [CBS10094 and CBS9756 (isolate HB1175 from Molnar et 
al. 2004)], clinical isolates are in black (case 1: L7537 and case 2: L998/16), the environmental isolate is in the striped box (L1024/16) and Tricho-
sporon asahii biofilm-control strains are in grey (L773, L7730 and L2589). The T. asahii biofilm quantification levels represent the threshold 
for detecting low, medium and high biofilm-forming isolates, respectively. Histograms depict the mean and standard deviation of 16 biofilm 
measurement replicates. *GM: Geometric Mean of MIC values from planktonic cells.
721Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 112(10), October 2017
as a predictor of virulence (Rajendran et al. 2016) and an-
tifungal resistance. Sequence analysis of the IGS1 region 
from the rDNA of the isolates and strains were carried 
out using a standard protocol (Sugita et al. 2002), and a 
phylogenetic tree was constructed using MEGA software 
version 7.0, with the addition of IGS1 rDNA sequences of 
Apiotrichum spp. and Trichosporon spp. retrieved from 
the GenBank database. Protein profiles were generated 
by MALDI-TOF mass spectrometry (MicroFlex, Bruker 
Daltonics, Bremen, Germany) according to the manufac-
turer’s recommendations [ethanol (70%) and formic acid 
(70%) extraction protocol]. Data analysis was performed 
using the Biotyper™ 3.1 software (Bruker Daltonics), 
with log score ≥ 2 considered as correct for species iden-
tification. Biofilm production was quantified according 
to a previously described method (Iturrieta-González et 
al. 2014), using three Trichosporon asahii strains isolat-
ed from blood cultures as controls that were previously 
classified as low (L773), medium (L7730), and high bio-
film producers (L2589). Briefly, biofilm formation was 
induced in 96-well polystyrene plates over 48 h, using 
RPMI-1640 medium. Quantification of mature biofilms 
was performed using the crystal violet staining method 
(Iturrieta-González et al. 2014). Two replicate plates on 
different occasions were assayed, totalling 16 wells an-
alysed. Antifungal susceptibility tests (AST) were per-
formed for amphotericin B (AMB), anidulafungin (ANI), 
fluconazole (FCZ), and voriconazole (VCZ). Against 
planktonic cells, AST was carried out with the reference 
broth microdilution method (CLSI 2008). For the bio-
film-producing cells, AST was carried out according to 
the protocol described by Iturrieta-González et al. (2014).
The phylogenetic analysis of IGS1 sequences (Supple-
mentary data, Fig. 1) confirmed the species identification 
by clustering our isolates in the Apiotrichum genus clade 
(bootstrap = 100). Furthermore, the Apiotrichum genus 
clade formed three distinct phylogenetic groups or geno-
types: the first group obtained from the bloodstream iso-
lated L7537 and the strain CBS10094; the Indian blood-
stream isolates formed a second group which was closely 
related to the first one; a third group comprised of the 
isolate L998/16 recovered from the patient with CF and 
the type strain CBS9756, isolated from an insect and an-
alysed as a microbial additive against mycotoxins in the 
food industry (Molnar et al. 2004). Despite its intra-spe-
cific genetic diversity, analysis by MALDI-TOF mass 
spectrometry showed that all isolates and strains of T. my-
cotoxinivorans (A. mycotoxinivorans) had similar spectral 
profiles and had correct species assignment with log score 
values > 2. A dendrogram based on the main spectrum 
profiles (MSP) from the Bruker’s database and from our 
isolates/strains gathered all T. mycotoxinivorans (A. my-
cotoxinivorans) MSPs in the same node (Supplementary 
data, Fig. 2). Four of five isolates/strains were character-
ised as low biofilm producers, in spite of some intraspe-
cific variations. Strikingly, the bloodstream isolate was 
characterised as a medium biofilm producer (Figure). 
Susceptibility tests of planktonic cells at 48 h readings 
showed high MIC values for AMB and ANI for all iso-
lates, with geometric means (GM) of 13.9 and 16 µg/mL, 
respectively, whereas FCZ and VCZ exhibited the best in 
vitro antifungal activities, with GM at 2.3 µg/mL and 0.12 
µg/mL, respectively (Figure). Although azoles derivatives 
showed good in vitro activity against planktonic cells of 
T. mycotoxinivorans (A. mycotoxinivorans), our investi-
gation suggests that microbial biofilms decreased their 
susceptibility to triazoles, which may partially influence 
the poor clinical response to antimicrobial therapy in T. 
mycotoxinivorans (A. mycotoxinivorans) infections.
In conclusion, while still considered rare, T. mycotox-
inivorans (A. mycotoxinivorans) may cause fungaemia 
and lung infections in patients exhibiting risk conditions 
for acquiring such infections. They are able to produce 
biofilms, with apparently negative impact on their sus-
ceptibility to triazoles. Finally, we provided new data 
about the genetic diversity of T. mycotoxinivorans (A. 
mycotoxinivorans), warranting further molecular epide-
miological studies to better understand the distribution 
of the different molecular types of T. mycotoxinivorans 
(A. mycotoxinivorans).
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